Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction
2021
Abstract
Background The identification of high-risk heart failure (HF) patients makes it possible to intensify their treatment. Our aim was to determine the prognostic value of a newly developed, high-sensitivity troponin I assay (Atellica(R), Siemens Healthcare Diagnostics) for patients with HF with reduced ejection fraction (HFrEF; LVEF II, NT-proBNP, hs-cTnI and urea) was 0.823 (p = 17 ng/l represent an independent increased risk of an adverse prognosis for patients with HFrEF and HFmrEF.
Determining a patient's hs-cTnI level adds prognostic value to NT-proBNP and clinical parameters.